PTS Diagnostics Named to Inc. Magazine’s 5000 Fastest Growing Private Companies List for the Fourth Time

PTS Diagnostics Named to Inc. Magazine’s 5000 Fastest Growing Private Companies List for the Fourth Time

Indianapolis, IN – September 15, 2014 — PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, has again been named to the Inc. 5000 list of the fastest-growing private companies in America. The Inc.5000 ranking is based on revenue growth over a three-year period. PTS Diagnostics earned its place on the list by growing its revenue by 80 percent from 2010 to 2013.

For PTS Diagnostics, who appears on the list as Polymer Technology Systems, this is the second consecutive year on the list and the fourth time in its history. PTS Diagnostics is the only Indiana medical device manufacturer that made the list in 2014 and has made the list four or more times.

“We are especially pleased with this distinction this year,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Our continued growth is a result of our commitment to manufacture and distribute a broad portfolio of diagnostic solutions for point-of-care healthcare providers. It’s gratifying for all of us to see our growth strategies validated in the marketplace and recognized by the media.”

PTS Diagnostics is experiencing rapid growth with its solutions that aid healthcare professionals in measuring HbA1c and glucose, and generating lipid (cholesterol) profiles, all at the point of care. “The essence of our mission is to improve health,” continued Huffstodt. “We can now provide fast, easy-to-use, accurate, point-of-care diagnostics for multiple key disease states, including high cholesterol and diabetes. Furthermore, we focus on the relationship with our distributors and customers encompassing our proven technology and point-of-care solutions.”

“We continue to build on this momentum,” concluded Huffstodt. “We have recently added new distribution partners to further expand our market reach; made key hires for our research, technology, sales, and marketing teams; and we have invested significantly in our manufacturing and quality control areas. We are excited to continue our ongoing commitment to providing a full suite of world-class point-of-care diagnostic solutions to healthcare professionals of all kinds, all around the world.”

PTS Diagnostics’ portfolio includes the following systems:
  • The CardioChek Plus analyzer addresses the connection between heart attack, stroke, and diabetes by providing simultaneous on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) and glucose screening results in as little as 90 seconds. The CardioChek Plus also calculates LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.
  • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

    About Inc. 5000 – The Inc. 500|5000 is a list of the fastest-growing private companies in the nation. Started in 1982, this prestigious list of the nation’s most successful private companies has become the hallmark of entrepreneurial success. The Inc. 5000 profiles are available on

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit or contact Tom Wiser at 317-870-5610.

    MKG001115 Rev.1 03/15